- Home
- IMVT vs PRVA Comparison
IMVT vs PRVA Comparison
Compare IMVT & PRVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMVT
- PRVA
- Stock Information
- Founded
- IMVT 2018
- PRVA 2007
- Country
- IMVT United States
- PRVA United States
- Employees
- IMVT N/A
- PRVA N/A
- Industry
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- PRVA Retail: Computer Software & Peripheral Equipment
- Sector
- IMVT Health Care
- PRVA Technology
- Exchange
- IMVT Nasdaq
- PRVA Nasdaq
- Market Cap
- IMVT 2.7B
- PRVA 3.1B
- IPO Year
- IMVT N/A
- PRVA 2021
- Fundamental
- Price
- IMVT $19.10
- PRVA $26.30
- Analyst Decision
- IMVT Buy
- PRVA Strong Buy
- Analyst Count
- IMVT 9
- PRVA 14
- Target Price
- IMVT $27.71
- PRVA $28.64
- AVG Volume (30 Days)
- IMVT 1.7M
- PRVA 903.8K
- Earning Date
- IMVT 11-06-2025
- PRVA 11-06-2025
- Dividend Yield
- IMVT N/A
- PRVA N/A
- EPS Growth
- IMVT N/A
- PRVA N/A
- EPS
- IMVT N/A
- PRVA 0.11
- Revenue
- IMVT N/A
- PRVA $1,900,071,000.00
- Revenue This Year
- IMVT N/A
- PRVA $96.90
- Revenue Next Year
- IMVT N/A
- PRVA $1.02
- P/E Ratio
- IMVT N/A
- PRVA $232.33
- Revenue Growth
- IMVT N/A
- PRVA 12.05
- 52 Week Low
- IMVT $12.72
- PRVA $17.40
- 52 Week High
- IMVT $32.10
- PRVA $26.09
- Technical
- Relative Strength Index (RSI)
- IMVT 68.97
- PRVA 73.73
- Support Level
- IMVT $17.03
- PRVA $23.72
- Resistance Level
- IMVT $18.34
- PRVA $24.87
- Average True Range (ATR)
- IMVT 0.91
- PRVA 0.70
- MACD
- IMVT 0.20
- PRVA 0.12
- Stochastic Oscillator
- IMVT 93.99
- PRVA 97.58
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
About PRVA Privia Health Group Inc.
Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.